2-{[(2-Furylmethyl)sulfonyl]methyl}-1,3-thiazole-4-carbohydrazide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-{[(2-Furylmethyl)sulfonyl]methyl}-1,3-thiazole-4-carbohydrazide
• 英文别名: 2-(furan-2-ylmethylsulfonylmethyl)-1,3-thiazole-4-carbohydrazide
• 化学式: C₁₀H₁₁N₃O₄S₂
• 分子量: 301.3
• InChiKey: STPIPIQKOKGEHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-碘吲哚醌 、 2-{[(2-Furylmethyl)sulfonyl]methyl}-1,3-thiazole-4-carbohydrazide 在 溶剂黄146 、 水 作用下， 以 溶剂黄146 为溶剂， 反应 16.17h， 以gave 32 mg of the title compound (63%) as a yellow solid in 99.3% purity by HPLC (Rt: 4.8, gradient of 10 min, MaxPlot detection between 230 and 400 nm)的产率得到2-(furan-2-ylmethylsulfonylmethyl)-N'-(5-iodo-2-oxoindol-3-yl)-1,3-thiazole-4-carbohydrazide
  参考文献：
  名称：

  OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS)

  摘要：

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢障碍，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖和多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式(I)的氧化吲哚肼衍生物调节，特别是抑制PTP的活性，尤其是PTP1B、TC-PTP、SHP和GLEPP-1的活性。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。

  公开号：

  US20100168101A1

文献信息

• Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
  申请人：Bombrun Agnes

  公开号：US20050043388A1

  公开（公告）日：2005-02-24

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢紊乱，包括1型和/或2型糖尿病、不适当的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖症、多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式(I)的氧化吲哚肼衍生物来调节，特别是抑制PTPs的活性，特别是PTP1B、TC-PTP、SHP和GLEPP-1。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。
• Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs)
  申请人：Laboratoires Serono SA

  公开号：US07696231B2

  公开（公告）日：2010-04-13

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢紊乱，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高甘油三酯血症、高胆固醇血症、肥胖症、多囊卵巢综合症（PCOS）。具体而言，本发明涉及使用式(I)的氧化吲哚肼衍生物来调节，特别是抑制PTPs的活性，特别是PTP1B、TC-PTP、SHP和GLEPP-1。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。(I)。
• US7696231B2
  申请人：——

  公开号：US7696231B2

  公开（公告）日：2010-04-13
• [EN] OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS)<br/>[FR] OXINDOLES HYDRAZIDES MODULATEURS DES PROTEINES TYROSINES PHOSPHATASES (PTPS)
  申请人：APPLIED RESEARCH SYSTEMS

  公开号：WO2003037328A1

  公开（公告）日：2003-05-08

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.(I).
• OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS)
  申请人：BOMBRUN Agnes

  公开号：US20100168101A1

  公开（公告）日：2010-07-01

  The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of oxindole hydrazide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs, in particular of PTP1B, TC-PTP, SHP and GLEPP-1. The present invention is furthermore related to novel oxindole hydrazide derivatives and method of preparation thereof.

  本发明涉及使用式(I)的氧化吲哚肼衍生物治疗和/或预防由胰岛素抵抗或高血糖介导的代谢障碍，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖和多囊卵巢综合症（PCOS）。特别地，本发明涉及使用式(I)的氧化吲哚肼衍生物调节，特别是抑制PTP的活性，尤其是PTP1B、TC-PTP、SHP和GLEPP-1的活性。本发明还涉及新的氧化吲哚肼衍生物及其制备方法。